Long-term Glycemic Control in Adult Participants Using Control-IQ Technology: Real-World Evidence

Rishi Graham1, Harsimran Singh2, Gabriel Alencar2, Lars Mueller2, Michelle Manning2, Kirstin White2, Alex Wheatcroft2, KC Carmelo2, Eliah Aronoff-Spencer1, Steph Habif2, Jordan Pinsker 2


The Control-IQ Observational (CLIO) Study is an ongoing prospective, real-world evaluation of the Tandem Diabetes Care t:slim X2 insulin pump with Control-IQ technology in people with T1D. We assessed baseline HbA1c and Glucose Management Indicator (GMI) derived from sensor data from adult participants who completed the 12-month CLIO study. Adults ages ≥18 years who had ≥75% overall CGM use during this time were included in the analysis. Outcomes were analyzed using a Wilcoxon test.

In all, 1,107 participants (882 prior pump and 225 prior MDI users), median age 41 years (IQR 30-54), 57.2% female met the inclusion criteria. Median GMI was significantly lower at 12 months (7.0% [6.7-7.4]) vs. baseline HbA1c (7.2% [6.7-8.1]) (p<0.0001). Participants ages 18-30 and 46-64 showed the greatest improvement from baseline (0.3% reduction) (p<0.0001), while older adults (≥65-years) showed the lowest GMI at study end (6.9% [6.6-7.2]). Prior MDI users reported higher HbA1c at baseline (7.7% [IQR=6.8-9.0]) vs. prior pumpers (7.2% [6.7-8.0]). However, GMI at 12 months reflected glycemic improvements across all prior therapy modalities (prior MDI=7.0% [6.7-7.3]; prior pump=7.1% [6.7-7.4]) (p<0.0001). This real-world evidence demonstrates significant glycemic improvements with Control-IQ technology in adults, regardless of prior therapy modality, that are sustained long-term across diverse groups of users.

Video Presentation

Watch the video from Dr. Jordan Pinsker for a review of the presentation delivered at the conference.